Dermatology
On the Surface: Restoring the Skin Barrier in Patients With AD
In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.
MD, MS
Amy Paller
Learning objectives
- Discuss how IL-4 and IL-13 contribute to epidermal barrier dysfunction, leading to the clinical features of AD
- Identify evidence regarding how skin barrier dysfunction, such as increased TEWL and plasma protein leakage, are associated with increased disease signs and skin symptom severity
- Review how certain biomarkers, such as CCL17, are important in assessing both the course and severity of AD
Tags
MAT-GLB-2506239 - 1.0 - 11/2025
About this expert
Dermatology
Amy Paller
MD, MS
Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US
See author’s profile